{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:29:44Z","timestamp":1790623784711,"version":"4.1.0"},"reference-count":36,"publisher":"Society of Nuclear Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,4,29]]},"DOI":"10.2967\/jnumed.125.269456","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T15:00:15Z","timestamp":1747926015000},"page":"jnumed.125.269456","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Outcomes of\n                    <sup>177<\/sup>\n                    Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Skeletal Metastases from Neuroendocrine Tumors: Insights from Real-World Experience"],"prefix":"10.2967","author":[{"given":"Kunal Ramesh","family":"Chandekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swayamjeet","family":"Satapathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Ballal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav Prasad","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubha Gadde","family":"Ravindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit Kumar","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrasekhar","family":"Bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"2025052910251028000_jnumed.125.269456v2.1","doi-asserted-by":"crossref","first-page":"e230331","DOI":"10.1530\/EC-23-0331","article-title":"Epidemiologic trends of and factors associated with overall survival in patients with neuroendocrine tumors over the last two decades in the USA","volume":"12","author":"Wu","year":"2023","journal-title":"Endocr Connect."},{"key":"2025052910251028000_jnumed.125.269456v2.2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30400"},{"key":"2025052910251028000_jnumed.125.269456v2.3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000457954","article-title":"Bone metastases in patients with neuroendocrine neoplasm: frequency and clinical, therapeutic, and prognostic relevance","volume":"106","author":"Scharf","year":"2018","journal-title":"Neuroendocrinology."},{"key":"2025052910251028000_jnumed.125.269456v2.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.060236"},{"key":"2025052910251028000_jnumed.125.269456v2.5","doi-asserted-by":"publisher","DOI":"10.1530\/EC-14-0119"},{"key":"2025052910251028000_jnumed.125.269456v2.6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000508633","article-title":"Bone metastases in neuroendocrine tumors: molecular pathogenesis and implications in clinical practice","volume":"111","author":"Cives","year":"2021","journal-title":"Neuroendocrinology."},{"key":"2025052910251028000_jnumed.125.269456v2.7","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000000267"},{"key":"2025052910251028000_jnumed.125.269456v2.8","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1200\/JCO.23.01529","article-title":"Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline","volume":"41","author":"Del Rivero","year":"2023","journal-title":"J Clin Oncol."},{"key":"2025052910251028000_jnumed.125.269456v2.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2025052910251028000_jnumed.125.269456v2.10","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet."},{"key":"2025052910251028000_jnumed.125.269456v2.11","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1200\/JCO.19.00980","article-title":"Prediction of progression-free survival in patients with advanced, well-differentiated, neuroendocrine tumors being treated with a somatostatin analog: the GETNE-TRASGU study","volume":"37","author":"Carmona-Bayonas","year":"2019","journal-title":"J Clin Oncol."},{"key":"2025052910251028000_jnumed.125.269456v2.12","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-016-0363-6"},{"key":"2025052910251028000_jnumed.125.269456v2.13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00432-021-03672-w","article-title":"Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)","volume":"148","author":"Swiha","year":"2022","journal-title":"J Cancer Res Clin Oncol."},{"key":"2025052910251028000_jnumed.125.269456v2.14","first-page":"437","article-title":"Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis","volume":"3","author":"Sabet","year":"2013","journal-title":"Am J Nucl Med Mol Imaging."},{"key":"2025052910251028000_jnumed.125.269456v2.15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/RLU.0b013e3182814ac1","article-title":"Dosimetric analyses of kidneys, liver, spleen, pituitary gland, and neuroendocrine tumors of patients treated with 177Lu-DOTATATE","volume":"38","author":"Gupta","year":"2013","journal-title":"Clin Nucl Med."},{"key":"2025052910251028000_jnumed.125.269456v2.16","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s00259-023-06544-2","article-title":"Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles","volume":"51","author":"Baum","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025052910251028000_jnumed.125.269456v2.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025052910251028000_jnumed.125.269456v2.18","doi-asserted-by":"publisher","DOI":"10.7150\/jca.1.80"},{"key":"2025052910251028000_jnumed.125.269456v2.19","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000506746","article-title":"177Lu-DOTATATE therapy of advanced pancreatic neuroendocrine tumors heavily pretreated with chemotherapy: analysis of outcome, safety, and their determinants","volume":"111","author":"Fr\u00f6ss-Baron","year":"2021","journal-title":"Neuroendocrinology."},{"key":"2025052910251028000_jnumed.125.269456v2.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009290"},{"key":"2025052910251028000_jnumed.125.269456v2.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00817-X"},{"key":"2025052910251028000_jnumed.125.269456v2.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003825"},{"key":"2025052910251028000_jnumed.125.269456v2.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.090373"},{"key":"2025052910251028000_jnumed.125.269456v2.24","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-006-9345-4"},{"key":"2025052910251028000_jnumed.125.269456v2.25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.2553"},{"key":"2025052910251028000_jnumed.125.269456v2.26","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/cancers12010206","article-title":"Outcomes of capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs)","volume":"12","author":"Thomas","year":"2020","journal-title":"Cancers (Basel)."},{"key":"2025052910251028000_jnumed.125.269456v2.27","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)","volume":"41","author":"Kunz","year":"2023","journal-title":"J Clin Oncol."},{"key":"2025052910251028000_jnumed.125.269456v2.28","first-page":"e230235","article-title":"Impact of sex on treatment decisions and outcome in patients with neuroendocrine neoplasms","volume":"31","author":"Beck","year":"2024","journal-title":"Endocr Relat Cancer."},{"key":"2025052910251028000_jnumed.125.269456v2.29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.263856"},{"key":"2025052910251028000_jnumed.125.269456v2.30","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00259-016-3533-z","article-title":"Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE","volume":"44","author":"Sansovini","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025052910251028000_jnumed.125.269456v2.31","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-3945-z"},{"key":"2025052910251028000_jnumed.125.269456v2.32","doi-asserted-by":"publisher","DOI":"10.3310\/hta22440"},{"key":"2025052910251028000_jnumed.125.269456v2.33","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2893-5"},{"key":"2025052910251028000_jnumed.125.269456v2.34","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00259-020-05127-9","article-title":"Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival","volume":"48","author":"Chantadisai","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025052910251028000_jnumed.125.269456v2.35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00572-6"},{"key":"2025052910251028000_jnumed.125.269456v2.36","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268617"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.269456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T13:25:21Z","timestamp":1748525121000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.269456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":36,"alternative-id":["10.2967\/jnumed.125.269456"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.269456","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]}}}